$HIMS (-1,68 %) / $LLY (+1,78 %)

RO and $LLY (+1,78 %) work together to offer cheaper ZEPBOUND vials

Ro announces a partnership with Eli Lilly $LLY (+1,78 %) to offer lower-cost, single-dose vials of Zepbound ® (tirzepatide) through LillyDirect ® , Lilly's self-pay pharmacy channel. Ro patients with eligible prescriptions will be able to purchase the FDA-approved weight loss medication directly through the platform.

This move is aimed at improving affordability and access to Zepbound, the first dual GIP/GLP-1 receptor agonist approved for the treatment of obesity.